August 7, 2026 · Form 4 insider transaction
Forbion Growth Opportunities Fund III Cooperatief U.A. sold 35,000,000 shares of Braveheart Bio, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.
Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock automatically converted into Common Stock on a one-for-4.38 basis without payment of consideration. The Series A Preferred Stock had no expiration date.; Forbion Ventures VII Management B.V. ("Forbion VII Director") is the director of Forbion Ventures Fund VII Cooperatief U.A. (the "Forbion Ventures VII") and may be deemed to have voting and dispositive power over the securities beneficially owned by the Forbion Ventures VII. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.